POINT Biopharma is a clinical-stage global pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Radioligands offer improved efficacy and superior safety profiles versus platform chemotherapy agents and can provide patients and their families the very best possible outcomes.
POINT today announced that it has successfully dosed multiple patients in its Phase 3 SPLASH study evaluating the efficacy of PNT2002, the Company’s investigational 177Lu-PSMA targeted radioligand therapy.
Globally focused radiopharmaceutical company achieves significant milestone to accelerate the operationalization of their 80,000 sq ft radioligand manufacturing facility
POINT announced today they signed a research and clinical supply agreement with TerraPower for the medical radioisotope actinium-225 (Ac-225)